112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 39; pp. S57 - S58
Main Authors Garcia-Manero, G, Fenaux, P, Al-Kali, A, Baer, M.R, Sekeres, M, Roboz, G, Gaidano, G, Scott, B, Greenberg, P, Platzbecker, U, Steensma, D.P, Kambhampati, S, Kreuzer, K.A, Godley, L, Collins, R, Atallah, E, Azarnia, N, Petrone, M.E, Snyder, B.R, Maniar, M, Silverman, L.R
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.04.2015
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:0145-2126
1873-5835
DOI:10.1016/S0145-2126(15)30113-2